A51 12 times more likely to be NWH compared to those walking at normal speed (Odds Ratio [OR]: 12.4 95% Confidence Interval [CI] 6.0 -25.6; p< 0.001), after controlling for age, gender, race, education, body mass index (BMI), income, and comorbidities. Further, the contribution of comorbidities in the model was significantly (p< 0.001) weakened when WS entered the model. ConClusions: Walking speed was an independent predictor of NWH status among community dwelling women and may be useful in the work setting to identify those at high risk of health related job loss. Further evaluation of the longitudinal predictive capability of WS is needed.
objeCtives: To develop a questionnaire for completion by patients presenting with shoulder instability. Methods: A draft 18 item questionnaire was developed using themes identified from interviews with patients (n= 20). The draft questionnaire was then tested on further groups of 20 patients attending an outpatient clinic, to which they had been referred with instability of the shoulder. Following modification resulting from patient feedback, the revised 12 item questionnaire was then tested in a prospective study of consecutive patients attending out-patient clinics for shoulder instability (n= 98). Patients completed patient-reported and clinical assessments pre-intervention (physiotherapy or surgery) and again at 6 months following treatment. The questionnaire was evaluated regarding its internal consistency, reproducibility, validity and responsiveness (sensitivity to change). Results:
The results provide evidence of good measurement properties of the questionnaire: Internal consistency -Cronbach's alpha was 0.91 at the pre-treatment assessment (n = 92) and 0.92 at follow-up (n = 64). Reproducibility -In the test-retest sample (n = 34), the correlation between the total scores for the questionnaire was high (r = 0.97, p < 0.0001), coefficient of reliability 5.7. Construct validity -The new questionnaire correlated well with the Constant and Rowe clinical scores both before operation and at the six-month follow-up. It also agreed significantly with the related parts of the SF36, particularly in physical function and pain. Responsiveness -The new questionnaire and the Rowe clinical score (but not the Constant) each achieved a large standardised effect size (≥ 0.8) that surpassed values obtained on relevant SF36 domains. ConClusions: We developed and tested a short patient-reported 12-item questionnaire ('score') which patients have found easy to complete and which provides reliable, valid and responsive information as to their perception of shoulder instability.
PMS59 chArAcTerISTIcS Of PATIenTS WITh rheuMATOId ArThrITIS SAMPled frOM A PATIenT AdvOcAcy OrgAnIzATIOn verSuS A cOnSuMer PAnel: IMPlIcATIOnS fOr PATIenT-cenTered reSeArch
Bolge S. 1 , Brown D. 2 , Goren A. 2 , Ginsberg S. 3 1 Janssen Scientific Affairs, LLC, Horsham, PA, USA, 2 Kantar Health, New York, NY, USA, 3 Creaky Joints, Upper Nyack, NY, USA objeCtives: Much information about the disease experience can only be obtained directly from patients. However, biases may be introduced to patient-reported research depending on the source of the sample. This analysis seeks to identify differences in demographic and disease characteristics between samples of patients with rheumatoid arthritis (RA) recruited through an advocacy organization and a consumer panel. Methods: Data were collected online from two groups of patients through self-administered questionnaires. Patients were recruited through the patient advocacy organization CreakyJoints and the Lightspeed Research consumer panel. Patients in both groups were U.S. adults (aged ≥ 18), diagnosed with RA, currently treated by a rheumatologist with disease modifying anti-rheumatic drugs (DMARDs), and with no history of biologic use but had discussed biologics with their physician. Results: A total of 243 patients completed the study. Of these, 101 were from the advocacy organization and 142 were from the consumer panel. Patients from the advocacy organization were younger (mean age, 46 vs. 57) and more likely to be female (93% vs. 80%), employed (53% vs. 31%), have a college degree (59% vs. 43%), and have commercial insurance (70% vs. 51%) than patients from the consumer panel (p< 0.05 for all comparisons). Patients from the advocacy organization also began experiencing RA symptoms more recently (mean years since symptom development, 10 vs. 15) and were more likely to be diagnosed by a rheumatologist (73% vs. 51%), have a caregiver (47% vs. 24%), and be non-adherent with medication (61% vs. 42%) than patients from the consumer panel (p< 0.05 for all comparisons). ConClusions: Members of patient advocacy organizations and consumer panels can differ demographically and in their disease characteristics. The potential impact of these differences on study results should be considered when developing a sampling and recruitment plan for patient-centered survey research. objeCtives: Identifying those at highest risk of poor outcomes is critical to population health management. The purpose of this study was to identify preoperative factors and comorbidities that are associated with those at risk of poor patientreported physical function recovery one year following total knee arthroplasty (TKA). Methods: Primary TKA unilateral procedures from a patient-reported total However, further methodological research is needed to achieve standardization of procedures.
PMS55 evAluATIng The degree TO WhIch AbIlITy TO PAy And heAlTh-relATed QuAlITy Of lIfe (hrQOl) Influence WIllIngneSS TO PAy (WTP) In PSOrIASIS And PSOrIATIc ArThrITIS PATIenTS
Dierick K. 1 , Worsfold A. 2 , Gillis L. 2 , Rose A. 2 1 GfK Disease Atlas, Brussels, Belgium, 2 GfK Disease Atlas, London, UK objeCtives: The aim of this study was to measure what matters most in WTP for a treatment, the patients' perception of their health status, their ability to pay, or a combination of both. Methods: 395 US patients diagnosed with either psoriasis (n= 151) or psoriatic arthritis (n= 247) completed a questionnaire as part of a broader survey of treatment of psoriasis/psoriatic arthritis in the US. The questionnaire included the EQ-5D-5L instrument and accompanying VAS. Patients were additionally asked to indicate by reference to the EQ-5D VAS scale the amount of money per month they would be willing to pay for treatments that would improve their health status by 10 points, retain their current health and prevent a decline in health status by 10 points. Annual household income information was also reported by patients. Patients were split into 3 equal groups based on their VAS. Results: Household income was a better predictor of WTP for a treatment; those patients with an annual income of less than $25000 were willing to pay the least (p< 0,001), whereas patients with an annual household income over $75000 would pay most (p< 0,001). Patients within the lowest VAS segment were prepared to pay significantly more for an improvement in their health status than patients within the other segments (p< 0,003). No significant differences were noted between groups to either retain health status or avoid health decline. For predicting WTP for an improvement in health status, a combination of low yearly income (< $25000) and the EQ-5D VAS was the best (sig < 0.001); WTP for a 10 VAS point improvement = $142 + (-$39,9*Low Income) + (-$0,7*VAS score). ConClusions: Both ability to pay and health status are valid predictors of willingness to pay for a treatment. Yet ability to pay is a better overall predictor of willingness to pay than HRQoL.
PMS56 funcTIOnAl STATuS And lAbOr PrOducTIvITy WITh TOfAcITInIb In PATIenTS WITh InAdeQuATe reSPOnSe TO nOn-bIOlOgIcAl dISeASe-MOdIfyIng AnTIrheuMATIc drugS (dMArd) verSuS AnTI-TuMOr necrOSIS fAcTOr drugS (AnTI-Tnf) In cOlOMbIA
Vargas-Valencia J. J. 1 , Vargas Zea N. 2 , Gutierrez-Ardila M. V. 2 1 Econopharma Consulting S. A. de C.V., Mexico City, Mexico, 2 Pfizer S.A.S., Bogotá, Colombia objeCtives: To evaluate the benefits in functional status and labor productivity of tofacitinib in patients with inadequate response to a non-biological DMARD vs anti-TNF in Colombia. Methods: The response to treatment was assessed by the change from baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) from baseline and works lost productivity: absenteeism and presenteeism (productivity reduction ≥ 50%) due patient's functional status, as reported by Chaparro del Moral R. 2012 and Hazes JM. 2010 who measured absenteeism according to functional status regardless of treatment received. Comparison between anti-TNF and tofacitinib (5mg BID) was done directly to adalimumab (heat-to-heat study) and indirectly (Bucher´s indirect comparisons adjusted method) vs other anti-TNF available in Colombia (certolizumab, etanercept, golimumab and infliximab) using methotrexate as reference therapy. A discrete event model that simulates six cohorts of 1,000 patients (each per treatment option) was developed; productivity hours lost was projected according to HAQ level (< 0.5; 0.5-0.87; > 0.87), during 52 weeks horizon. Variations in HAQ levels (basal and weekly mean chance), absenteeism and presenteeism hours were probabilistically generated assuming a normal distribution. The results obtained with the anti-TNF's are grouped and weighted given their market share as reported in the SISMED by the Health Ministry. Results: Improvement in HAQ-DI score at 3, 6, 9 and 12 months from baseline with tofacitinib and anti -TNF were 61.9, 48.7, 65.2 and 53.2%; and, 49.5, 42.7, 57.1 and 47.1%, respectively (t-test at 52 weeks, p< 0.001). As result of these reductions, the hours of absenteeism/presenteeism losses along the 52-week horizon were obtained, at last observation week: 2.72/2.67 and 4.04/7.23 hours with tofacitinib and anti-TNF respectively. ConClusions: The superior reduction in HAQ-DI scale at 52 weeks obtained with Tofacitinib in patients with inadequate response to a non-biological DMARD results in a greater reduction in work lost productivity, presenteeism and absenteeism, compared to anti-TNF available in Colombia.
PMS57 WAlKIng SPeed PredIcTS WOrK STATuS due TO heAlTh In cOMMunITy dWellIng WOMen: The OSTeOArThrITIS InITIATIve (OAI)
Kirkness C. S. , Ren J. University of Illinois, Peoria, IL, USA objeCtives: Early identification of declining health in working adults with osteoarthritis (OA) may allow targeted interventions that prevent health related job loss. Usual walking speed(WS) is a predictor of health status in adults ≥ 65 years4 1 and may also be a useful simple predictor of work status in younger adults with OA. The study purpose was to determine whether WS is an independent predictor of work status in women with or at risk for osteoarthritis adjusting for covariates. Methods: Participants were 2,634 women (23% African American) age 45-79 years with baseline WS (Self-selected 20 meters [m]) in the OAI study. Logistic regression examined WS as a predictor of work status (working versus not working due to health [NWH]) for those walking at slow (< 1.10 meters/second[s]), moderate (1.1-1.29 m/s) and normal (> 1.3 m/s) speeds, adjusting for demographics and other confounders. Results: Of the 2,634 women (mean age 60.0, Standard Deviation [SD] 9.1, years), 57.9% (1,533) were working, 36.0% (952) were not working for other reasons and 5.6% (149) were NWH. WS was significantly faster in those working compared to those NWH, (mean speed 1.33 m/s vs. 1.08 m/s; p< 0.001). Compared to women with normal WS (> 1.3 m/s), those considered slow walkers (WS < 1.10) were
